Similar articles

• Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children.

  Hyams J, Crandall W, Kugathasan S, Griffiths A, Olson A, Johanns J, Liu G, Travers S, Heuschkel R, Markowitz J, Cohen S, Winter H, Veereman-Wauters G, Ferry G, Baldassano R; REACH Study Group. Hyams J, et al. Gastroenterology. 2007 Mar;132(3):863-73; quiz 1165-6. doi: 10.1053/j.gastro.2006.12.003. Epub 2006 Dec 3. Gastroenterology. 2007. PMID: 17324398 Clinical Trial.
• Combination therapy with infliximab and immunomodulators: is the glass half empty?

  Deshpande AR, Abreu MT. Deshpande AR, et al. Gastroenterology. 2008 Jun;134(7):2161-3. doi: 10.1053/j.gastro.2008.04.029. Epub 2008 May 13. Gastroenterology. 2008. PMID: 18482585 No abstract available.
• Maintenance infliximab infusions forever?

  Lee SD, Surawicz CM. Lee SD, et al. Am J Gastroenterol. 2002 Nov;97(11):2917-8. doi: 10.1111/j.1572-0241.2002.07041.x. Am J Gastroenterol. 2002. PMID: 12425570 No abstract available.
• [Indications and results of infliximab in Crohn's disease].

  Karoui S, Boubaker J, Filali A. Karoui S, et al. Tunis Med. 2004 Dec;82(12):1057-63. Tunis Med. 2004. PMID: 15822505 Review. French.
• Infliximab: lifetime use for maintenance is appropriate in Crohn's Disease. PRO: maintenance therapy is superior to episodic therapy.

  Lichtenstein GR. Lichtenstein GR. Am J Gastroenterol. 2005 Jul;100(7):1433-5. doi: 10.1111/j.1572-0241.2005.50622_1.x. Am J Gastroenterol. 2005. PMID: 15984959 Review. No abstract available.